|
1.
|
Krejsek J: News in the pathogenesis of
multiple sclerosis. What is hidden behind the disability of MS
patients. Remedia. 2014:S2–S4. 2014.(In Czech).
|
|
2.
|
Cree B and Vollmer TL: Clinically isolated
syndrome: Evaluation, risk stratification, and treatment decisions.
Adv Stud Med. 8:257–265. 2008.
|
|
3.
|
Garcea O, Villa A, Cáceres F, Adoni T,
Alegría M, Barbosa Thomaz R, Buzo R, Llamas López L and Rivera
Kindel M: Early treatment of multiple sclerosis: A Latin American
experts meeting. Mult Scler. 15(Suppl 3): S1–S12. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Schumacher GA, Beebe G, Kibler RF, Kurland
LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW
and Willmon TL: Problems of experimental trials of therapy in
multiple sclerosis: report by the panel on the evaluation of
experimental trials of therapy in multiple sclerosis. Ann N Y Acad
Sci. 122:552–568. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Poser CM, Paty DW, Scheinberg L, McDonald
WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH and
Tourtellotte WW: New diagnostic criteria for multiple sclerosis:
Guidelines for research protocols. Ann Neurol. 13:227–231. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
McDonald WI, Compston A, Edan G, Goodkin
D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH,
Reingold SC, et al: Recommended diagnostic criteria for multiple
sclerosis: guidelines from the International Panel on the diagnosis
of multiple sclerosis. Ann Neurol. 50:121–127. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Polman CH, Reingold SC, Edan G, Filippi M,
Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor
PW, et al: Diagnostic criteria for multiple sclerosis: 2005
revisions to the ‘McDonald Criteria’. Ann Neurol. 58:840–846. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Polman CH, Reingold SC, Banwell B, Clanet
M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M,
Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2010
revisions to the McDonald criteria. Ann Neurol. 69:292–302. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Tintoré M: Rationale for early
intervention with immunomodulatory treatments. J Neurol. 255(Suppl
1): 37–43. 2008. View Article : Google Scholar
|
|
10.
|
Miller JR: The importace of early
diagnosis of multiple sclerosis. J Manag Care Pharm. 10:S4–S11.
2004.PubMed/NCBI
|
|
11.
|
Kroksveen AC, Guldbrandsen A, Vedeler C,
Myhr KM, Opsahl JA and Berven FS: Cerebrospinal fluid proteome
comparison between multiple sclerosis patients and controls. Acta
Neurol Scand Suppl. 195:90–96. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ
and Berven FS: Proteomics of human cerebrospinal fluid: discovery
and verification of biomarker candidates in neurodegenerative
diseases using quantitative proteomics. J Proteomics. 74:371–388.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ottervald J, Franzén B, Nilsson K,
Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G,
Végvári A, Harris RA, et al: Multiple sclerosis: identification and
clinical evaluation of novel CSF biomarkers. J Proteomics.
73:1117–1132. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kroksveen AC, Aasebø E, Vethe H, Van Pesch
V, Franciotta D, Teunissen CE, Ulvik RJ, Vedeler C, Myhr KM,
Barsnes H, et al: Discovery and initial verification of
differentially abundant proteins between multiple sclerosis
patients and controls using iTRAQ and SID-SRM. J Proteomics.
78:312–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Comabella M, Fernández M, Martin R,
Rivera-Vallvé S, Borrás E, Chiva C, Julià E, Rovira A, Cantó E,
Alvarez-Cermeño JC, et al: Cerebrospinal fluid chitinase 3-like 1
levels are associated with conversion to multiple sclerosis. Brain.
133:1082–1093. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Stoop MP, Singh V, Dekker LJ, Titulaer MK,
Stingl C, Burgers PC, Sillevis Smitt PA, Hintzen RQ and Luider TM:
Proteomics comparison of cerebrospinal fluid of relapsing remitting
and primary progressive multiple sclerosis. PLoS One. 5:e124422010.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Cox J and Mann M: MaxQuant enables high
peptide identification rates, individualized p.p.b.-range mass
accuracies and proteome-wide protein quantification. Nat
Biotechnol. 26:1367–1372. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Cox J, Neuhauser N, Michalski A, Scheltema
RA, Olsen JV and Mann M: Andromeda: a peptide search engine
integrated into the MaxQuant environment. J Proteome Res.
10:1794–1805. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Cox J, Hein MY, Luber CA, Paron I, Nagaraj
N and Mann M: Accurate proteome-wide label-free quantification by
delayed normalization and maximal peptide ratio extraction, termed
MaxLFQ. Mol Cell Proteomics. 13:2513–2526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: affy - analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Yang YH, Dudoit S, Luu P, Lin DM, Peng V,
Ngai J and Speed TP: Normalization for cDNA microarray data: a
robust composite method addressing single and multiple slide
systematic variation. Nucleic Acids Res. 30:e152002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Christin C, Hoefsloot HC, Smilde AK,
Hoekman B, Suits F, Bischoff R and Horvatovich P: A critical
assessment of feature selection methods for biomarker discovery in
clinical proteomics. Mol Cell Proteomics. 12:263–276. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Clough T, Thaminy S, Ragg S, Aebersold R
and Vitek O: Statistical protein quantification and significance
analysis in label-free LC-MS experiments with complex designs. BMC
Bioinformatics. 13(Suppl 16): S62012. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Lipsy RJ, Schapiro RT and Prostko CR:
Current and future directions in MS management: key considerations
for managed care pharmacists. J Manag Care Pharm. 15(Suppl A):
S2–S15; quiz S16–S17. 2009.PubMed/NCBI
|
|
25.
|
Mareš J: Early treatment of multiple
sclerosis - treatment of clinically isolated syndrome, conditions
of early diagnosis and treatment of multiple sclerosis. Remedia.
2011.S5–S6, (In Czech).
|
|
26.
|
Tintoré M, Rovira A, Río J, Nos C, Grivé
E, Téllez N, Pelayo R, Comabella M, Sastre-Garriga J and Montalban
X: Baseline MRI predicts future attacks and disability in
clinically isolated syndromes. Neurology. 67:968–972. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Fisniku LK, Brex PA, Altmann DR, Miszkiel
KA, Benton CE, Lanyon R, Thompson AJ and Miller DH: Disability and
T2 MRI lesions: a 20-year follow-up of patients with relapse onset
of multiple sclerosis. Brain. 131:808–817. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Pérez-Miralles F, Sastre-Garriga J,
Tintoré M, Arrambide G, Nos C, Perkal H, Río J, Edo MC, Horga A,
Castilló J, et al: Clinical impact of early brain atrophy in
clinically isolated syndromes. Mult Scler. 19:1878–1886. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Sastre-Garriga J, Tintoré M, Rovira A,
Grivé E, Pericot I, Comabella M, Thompson AJ and Montalban X:
Conversion to multiple sclerosis after a clinically isolated
syndrome of the brainstem: cranial magnetic resonance imaging,
cerebrospinal fluid and neurophysiological findings. Mult Scler.
9:39–43. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Neuteboom RF, Boon M, Catsman Berrevoets
CE, Vles JS, Gooskens RH, Stroink H, Vermeulen RJ, Rotteveel JJ,
Ketelslegers IA, Peeters E, et al: Prognostic factors after a first
attack of inflammatory CNS demyelination in children. Neurology.
71:967–973. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Tintoré M, Rovira A, Río J, Tur C, Pelayo
R, Nos C, Téllez N, Perkal H, Comabella M, Sastre-Garriga J, et al:
Do oligoclonal bands add information to MRI in first attacks of
multiple sclerosis? Neurology. 70:1079–1083. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Ingram G, Loveless S, Howell OW, Hakobyan
S, Dancey B, Harris CL, Robertson NP, Neal JW and Morgan BP:
Complement activation in multiple sclerosis plaques: an
immunohistochemical analysis. Acta Neuropathol Commun. 2:532014.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Ekdahl NK, Blomberg C, Henningsson JA,
Dahle C, Håkanssone I, Sandholm K and Ernerudh J: Systemic and
intrathecal complement activation in multiple sclerosis and
Guillan-Barré syndrome. Mol Immunol. 46:28482009. View Article : Google Scholar
|
|
34.
|
Ingram G, Hakobyan S, Robertson NP and
Morgan BP: Complement in multiple sclerosis: its role in disease
and potential as a biomarker. Clin Exp Immunol. 155:128–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Hinsinger G, Galéotti N, Nabholz N, Urbach
S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G,
et al: Chitinase 3-like proteins as diagnostic and prognostic
biomarkers of multiple sclerosis. Mult Scler. 21:1251–1261. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Greenstein J and Cunningham T:
Neuroprotective, anti-inflammatory and immune Tolerizing properties
of peptides derived from diffusion survival Evasion protein
(DSEP)/Dermcidin. Neurology. 82:P1.1752014.
|
